Genmab Marketing Mix

Genmab has achieved significant commercial success with its innovative medicines, notably EPKINLY®/TEPKINLY® (epcoritamab) for lymphoma and Tivdak® (tisotumab vedotin-tftv) for cervical cancer. These therapies are key drivers of Genmab's revenue and demonstrate its capacity to deliver groundbreaking treatments.

The commercialization of these products highlights Genmab's strong research and development pipeline translating into tangible patient outcomes and market presence. For instance, EPKINLY® received FDA approval in May 2023 and has seen strong uptake. Tivdak®, approved by the FDA in October 2021, continues to gain traction in the cervical cancer market.

• EPKINLY®/TEPKINLY® (epcoritamab): A bispecific antibody offering a novel treatment approach for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
• Tivdak® (tisotumab vedotin-tftv): An antibody-drug conjugate targeting tissue factor, approved for adult patients with recurrent or metastatic cervical cancer.
• Revenue Contribution: These advanced therapies are crucial revenue generators, reflecting successful market penetration and patient access.
• Therapeutic Advancement: Both medicines represent significant progress in their respective oncology indications, addressing unmet medical needs.

Genmab’s co-development strategy is a cornerstone of its innovation, enabling the company to bring novel therapies to market efficiently. Many of Genmab's key products are the result of strategic partnerships with leading pharmaceutical companies. This approach allows Genmab to tap into the vast resources and expertise of its collaborators, significantly de-risking and accelerating the development process. For instance, the successful commercialization of DARZALEX® with Johnson & Johnson, EPKINLY® with AbbVie, and Tivdak® with Pfizer highlights the power of these alliances. These collaborations are crucial for managing the substantial financial investment and regulatory hurdles inherent in bringing new medicines to global patient populations.

These strategic collaborations are not just about sharing costs; they are about amplifying reach and impact. By partnering, Genmab gains access to extensive clinical trial networks, established regulatory affairs teams, and robust global commercialization infrastructure. This significantly speeds up the journey from lab to patient. For example, the global launch and market penetration of products like DARZALEX® are testament to the combined strengths of Genmab's scientific innovation and its partners' market access capabilities. This model is particularly vital in the competitive oncology landscape, where rapid advancement and broad patient access are paramount.

The financial implications of this co-development model are substantial. While Genmab retains significant upside through royalty agreements and milestone payments, it also benefits from shared development expenses. This financial pragmatism allows Genmab to maintain a strong balance sheet while pursuing an ambitious pipeline. In 2024, Genmab reported significant revenue generated from its partnered products, underscoring the commercial success of this strategy. The ability to share the significant upfront and ongoing costs of late-stage clinical trials and regulatory submissions is a key enabler of Genmab's growth and its capacity to invest in future research and development.

Key aspects of Genmab's co-development and innovation include:

• Strategic Partnerships: Collaborations with major pharmaceutical firms like Johnson & Johnson, AbbVie, and Pfizer for key products such as DARZALEX®, EPKINLY®, and Tivdak®.
• Resource Leverage: Accessing partners' extensive resources for clinical trials, regulatory approvals, and global market access.
• Risk and Cost Sharing: Distributing the substantial financial burdens and risks associated with drug development and commercialization.
• Accelerated Market Access: Expediting the delivery of innovative therapies to a wider patient base worldwide.

Genmab invests in targeted medical education and support programs to ensure healthcare professionals fully understand and appropriately utilize their advanced therapies. These initiatives, including educational materials and symposia, are crucial for complex treatments. For instance, Genmab's commitment to education is evident in programs designed to inform oncologists and hematologists about the nuances of CAR T-cell therapy administration and patient management. In 2024, Genmab allocated a significant portion of its marketing budget to these educational efforts, reflecting their importance in market penetration and patient safety.

These programs are designed to enhance the understanding of Genmab's innovative treatments, focusing on efficacy and patient outcomes. By providing comprehensive resources, Genmab empowers clinicians to make informed treatment decisions. For example, educational modules on DARZALEX (daratumumab) have been instrumental in detailing infusion protocols and managing potential side effects, leading to improved patient experiences.

• Medical Education: Development of specialized content and training for healthcare providers on novel therapeutic mechanisms and administration.
• Symposia and Workshops: Hosting events for peer-to-peer learning and discussion of clinical data and best practices.
• Patient Support Resources: Providing information and tools to assist patients and caregivers in navigating complex treatment journeys.
• Data-Driven Education: Utilizing real-world evidence and clinical trial results to inform educational content and support program development.

Genmab's corporate digital presence and public relations are crucial for conveying its scientific advancements and ethical commitments. A robust corporate website serves as a central hub for detailed pipeline information and financial reports, ensuring transparency for stakeholders. For instance, as of early 2024, Genmab's website prominently features its innovative antibody technologies and clinical trial progress, attracting significant investor attention.

Leveraging professional social media, particularly LinkedIn, allows Genmab to directly engage with a global audience. This platform is instrumental in sharing company news, highlighting employee achievements, and reinforcing its reputation as an industry leader. In 2023, Genmab's LinkedIn presence saw a notable increase in engagement, reflecting growing interest in its scientific breakthroughs and corporate culture.

Strategic public relations efforts are vital for shaping Genmab's narrative and building trust. By actively participating in industry events and issuing press releases on key milestones, Genmab effectively communicates its corporate vision and dedication to patient welfare. This proactive approach helps to solidify its brand image and reach diverse audiences, from potential collaborators to future employees, underscoring its commitment to advancing cancer treatment.

• Website: Acts as a primary source for pipeline updates and corporate vision.
• Social Media (LinkedIn): Facilitates direct engagement with investors and potential talent.
• Public Relations: Builds brand awareness and reinforces leadership in antibody science.
• Audience Reach: Targets investors, employees, and the general public effectively.